Active surveillance for low-risk prostate cancer worldwide: The PRIAS study

Meelan Bul, Xiaoye Zhu, Riccardo Valdagni, Tom Pickles, Yoshiyuki Kakehi, Antti Rannikko, Anders Bjartell, Deric K. Van Der Schoot, Erik B. Cornel, Giario N. Conti, Egbert R. Boevé, Frédéric Staerman, Jenneke J. Vis-Maters, Henk Vergunst, Joris J. Jaspars, Petra Strölin, Erik Van Muilekom, Fritz H. Schröder, Chris H. Bangma, Monique J. Roobol

Research output: Contribution to journalArticlepeer-review


Background: Overdiagnosis and subsequent overtreatment are important side effects of screening for, and early detection of, prostate cancer (PCa). Active surveillance (AS) is of growing interest as an alternative to radical treatment of low-risk PCa. Objective: To update our experience in the largest worldwide prospective AS cohort. Design, setting, and participants: Eligible patients had clinical stage T1/T2 PCa, prostate-specific antigen (PSA) ≤10 ng/ml, PSA density 6 at repeat biopsy. Recommendation for treatment was triggered in case of PSA doubling time

Original languageEnglish
Pages (from-to)597-603
Number of pages7
JournalEuropean Urology
Issue number4
Publication statusPublished - Apr 2013


  • Active surveillance
  • Prognostic factors
  • Prostate-specific antigen
  • Prostatic neoplasms
  • Reclassification

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Active surveillance for low-risk prostate cancer worldwide: The PRIAS study'. Together they form a unique fingerprint.

Cite this